Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L. Scott, Mitchell E. Horwitz, H. Joachim Deeg et al.|Journal of Clinical Oncology|2017Cited by 664
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S. Hourigan, Mitchell E. Horwitz, Laura W. Dillon et al.|Journal of Clinical Oncology|2019Cited by 441
Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) SurveyAlice Chan, M. Teresa de la Morena, Jennifer W. Leiding et al.|Frontiers in Immunology|2020Cited by 81
Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-LearningElizabeth F. Krakow, Erica E. M. Moodie, Michael Hemmer et al.|American Journal of Epidemiology|2017Cited by 42
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M. Al Malki, Antonio Jiménez, Stephanie Bo‐Subait et al.|Journal of Clinical Oncology|2025Cited by 23